Patents by Inventor Merouane Bencherif

Merouane Bencherif has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharamceutical compositions for prevention and treatment of tourette's syndrome
    Patent number: 5731314
    Abstract: Patients susceptible to or suffering from Tourette's syndrome are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-?3-(5-methoxypyridin)yl!-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-?3-(5-methoxypyrindin)yl!-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-?3-(6-methylpyrindin)yl!-3-butene-1-amine.
    Type: Grant
    Filed: January 6, 1995
    Date of Patent: March 24, 1998
    Inventors: Merouane Bencherif, Patrick Michael Lippiello, William Scott Caldwell, Gary Maurice Dull
  • Pharmaceutical compositions for prevention and treatment of ulcerative colitis
    Patent number: 5604231
    Abstract: Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.
    Type: Grant
    Filed: January 6, 1995
    Date of Patent: February 18, 1997
    Inventors: Carr J. Smith, Patrick M. Lippiello, Merouane Bencherif, William S. Caldwell, Gary M. Dull
  • Pharmaceutical compositions for the treatment of central nervous system disorders
    Patent number: 5583140
    Abstract: Patients susceptible to or suffering from central nervous system disorders (e.g., neurodegenerative diseases including presenile dementia, senile dementia of the Alzheimer's type, and Parkinsonism including Parkinson's disease, and other CNS disorders including attention deficit disorder, schizophrenia and Tourette's syndrome) are treated by administering an effective amount of 2-azabicyclo[2.2.1]hept-5-ene and 2-azabicyclo[2.2.2]oct-5-ene compounds.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: December 10, 1996
    Inventors: Merouane Bencherif, William S. Caldwell, Gary M. Dull, Patrick M. Lippiello
  • Depolarizing skeletal muscle relaxants
    Patent number: 5559124
    Abstract: Compounds such as 2-acetoxymethylquinuclidine are useful as locally acting and highly selective muscle relaxants. Each compound, when administered intravenously, acts to bind to musculoskeletal nicotinic receptor sites in a reversible manner causing transient depolarization, and hence provides for reversible muscle relaxation to a patient during anesthesia.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 24, 1996
    Inventors: Merouane Bencherif, Patrick M. Lippiello, William S. Caldwell
  • Depolarizing skeletal muscle relaxants
    Patent number: 5510355
    Abstract: Compounds such as 5-chloronicotine, 5-fluoronornicotine, anabaseine, 5-fluoroanabaseine, 2-acetoxymethylquinuclidine or!2-(3-pyridyl)-quinuclidine are useful as locally acting and highly selective muscle relaxants. Each compound, when administered intravenously, acts to bind to musculoskeletal nicotinic receptor sites in a reversible manner causing transient depolarization, and hence provides for reversible muscle relaxation to a patient during anesthesia.
    Type: Grant
    Filed: September 6, 1994
    Date of Patent: April 23, 1996
    Inventors: Merouane Bencherif, Patrick M. Lippiello, William S. Caldwell